In the US, the first people could possibly receive the vaccine for Covid-19 as early as December 11 or 12. Moncef Slaoui, the main scientific advisor to the White House’s vaccine efforts, promised that in an interview on Sunday.
Slaoui said in an interview with CNN host Jake Tapper on State of the Union show that he and his colleagues hoped to have the vaccine shipped to vaccination sites within 24 hours of receiving approval from the FDA.
Slaoui assumes that the lives of Americans could return to normal as early as May
A panel of outside experts advising the FDA is expected to meet on December 10th to discuss Pfizer and Biontech’s application for emergency approval. It is not clear how quickly the FDA will respond to the panel’s recommendation. According to the manufacturer, clinical studies are said to have shown that the vaccine is 95 percent effective in preventing people from developing Covid-19.
Slaoui previously said he expected 20 million people to be vaccinated in December, and up to 30 million more people each month thereafter. He assumes that Americans will be able to return to normal as early as May. Due to the high effectiveness of the vaccine, real herd immunity may be possible.
In Germany, too, a vaccine is expected to be approved by the end of the year
The first people in Germany could soon be vaccinated too. “We have the well-founded hope that a vaccine will be approved in Germany by the end of the year,” said the Federal Ministry of Health of “Bild”. Chancellor Angela Merkel last expected a corona vaccine to be approved in Europe in December or “very soon after the turn of the year”.
In Europe, the European Medicines Agency (EMA) decides on approval. She has announced that she will organize a virtual meeting, accessible to all interested parties, on December 11th to explain the processes for the development, evaluation, approval and safety monitoring of Covid-19 vaccines in the EU. In addition to Pfizer and Biontech, two other vaccines are currently being examined for approval: the candidate mRNA-1273 from Moderna and the vaccine from Oxford University and the company AstraZeneca.
It is also still unclear who can be vaccinated first until enough vaccine is available for everyone who wants to.
This text has been translated from English and edited. You can find the original version here.